GN

Giridhar Nagardona

Active Director Designated Partner DIN 10609925
DIN 10609925 First appointment Apr 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Giridhar Nagardona

Data last updated:

Giridhar Nagardona is a Designated Partner at Yunan Pharmaceuticals Llp (since 2024). The company operates in Pharma.

DIN 10609925
Primary Designation Designated Partner
Industry Pharma
First Appointment 29 Apr 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner29 Apr 20242024Active

Board colleagues of Giridhar Nagardona

NameDINCompanyDesignation
Sarada Yeddanapudi11222972Yunan Pharmaceuticals LlpDesignated Partner
Srinivas Tatavarthi10609924Yunan Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Yunan Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Giridhar Nagardona

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Giridhar Nagardona

Giridhar Nagardona currently holds 1 directorship: Yunan Pharmaceuticals Llp (Designated Partner, since 29 Apr 2024).

Giridhar Nagardona was first appointed on 29 Apr 2024 as Designated Partner at Yunan Pharmaceuticals Llp.

The current boards of Giridhar Nagardona's companies include Sarada Yeddanapudi (Yunan Pharmaceuticals Llp), Srinivas Tatavarthi (Yunan Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available